Supriya Lifescience Ltd

ESG Rating Disclosure

• CRISIL ESG Rating: 'CRISIL ESG 6 5' in 'Strong' category; rating is voluntary.

Supriya Lifescience Ltd — Trading Window Closure from Oct 01, 2026 until 48 hours after declaration of Unaudited Financial Results for the quarter and half year ending Sep 30, 2026

AGM Details

• AGM held on 24 Sep 2026 at 3:00 PM IST via VC/OAVM.
• Meeting concluded at 3:50 PM IST.
• Record date for final dividend fixed as 4 Sep 2026.
• Notice and reports dispatched on 1 Sep 2026; remote e-voting available.

Resolutions

• Item 1: Adopt Audited Financial Statements for FY2025-26.
• Item 2: Declare final dividend of Re 1.00 per equity share.
• Item 3: Re-appoint Dr. Saloni Satish Wagh as Director.
• Item 4: Ratify Cost Auditors' remuneration for FY2026-27.
• Item 5: Re-appoint Ms. Shivani Satish Wagh as Director.

Voting Results

• Item 1 passed; assent 99.9974%, dissent 0.0026%.
• Item 2 passed; assent 99.9973%, dissent 0.0027%.
• Item 3 passed; assent 99.7621%, dissent 0.2379%.
• Item 4 passed; assent 99.9963%, dissent 0.0037%.
• Item 5 passed; assent 99.9958%, dissent 0.0042%.

Dividend

• Final dividend of Re 1.00 per equity share approved.

Director Changes

• Dr. Saloni Satish Wagh reappointed as Director.
• Ms. Shivani Satish Wagh reappointed as Director.

Auditor Arrangements

• Remuneration of Cost Auditors for FY2026-27 ratified.

Court order

• High Court of Bombay granted provisional release of 200 kg Ketamine Hydrochloride under Shipping Bill 3780061.
• Deposit ₹72 lakh with the Assistant Commissioner of Customs within one week.
• Adjudication and criminal proceedings may continue under applicable law.
• Court allowed follow-up under Section 52A NDPS Act.
• Company will inform exchanges of further developments.
• Judgment dated September 22, 2026.

Key Update

• Company operates in a single segment: Pharmaceuticals.
• Omission of segment details in the Aug 13, 2026 quick results was a technical error.

Meeting Details

• Date and time: Friday, September 25, 2026, 11:00 AM–12:00 Noon.
• Format: Group meeting; Mode: Virtual.
• Event: Investors Group Meeting.

Participants

• Key company participants: Investor relations/management officials.
• Attendees include company officials; no personal names provided.

Purpose

• Purpose: Analyst/institutional investor interaction.

Additional Notes

• Investor presentation available on stock exchanges and the company website.

Meeting Details

• Date & time: Thursday, September 17, 2026, 11:00 AM–12:00 NOON
• Type/Format: Group meeting
• Mode: Virtual
• Organizer: Investors Group Meeting
• Purpose: Analyst/institutional investor interaction
• Key company participants: Officials (management) to participate
• Presentation: Investor Presentation uploaded on exchanges and company website

AGM and annual report access

• 18th AGM of Supriya Lifescience to be held on Sep 24, 2026 at 3:00 PM IST via VC/OAVM.
• Soft copy of Annual Report for 2025-26 and AGM Notice available at the company site and exchanges.
• Emails to non-registered members about the AR will be sent by MUFG Intime India as of Aug 21, 2026.
• Members should register email addresses with their DP or RTA to receive future communications.
• RTA contact for queries: Investor.helpdesk@in.mpms.mufg.com.
• Annual Report and Notice accessible at supriyalifescience.com/ir-annual-report-return.php.

Judicial status

• Matter regarding General Manager - Sales & Marketing remains sub judice and awaiting hearing.
• No new orders or developments reported by the court to date.
• Earlier status communicated via earnings call and transcripts on Aug 14 and Aug 18, 2026.
• Company will inform Stock Exchanges of any material development, including court orders.